Tuberculosis caused by Mycobacterium tuberculosis has emerged as the biggest curse of our time causing significant morbidity and mortality. Increasing resistance in mycobacterium to existing drugs calls for exploration of metabolic pathways for finding novel drug targets and also for prioritization of known drug targets. Recent advances in molecular biology, bioinformatics and structural biology coupled with availability of M. tuberculosis genome sequence have provided much needed boost to drug discovery process. This review provides a glimpse of attractive drug targets for development of anti-mycobacterial drug development.
Keywords: Tuberculosis, Mycobacterium tuberculosis, multi-drug resistance, current therapy, novel drug targets, epidemiologists, anti-tubercular, para-aminosalicylic acid, host-pathogen, capreomycin, Mycobacterium, Isoniazid, dehydrogenases, menaquinone
Rights & PermissionsPrintExport